<DOC>
	<DOCNO>NCT00253266</DOCNO>
	<brief_summary>This assessment efficacy venlafaxine-HCL augmentation neuroleptic quetiapine treatment resistant depression .</brief_summary>
	<brief_title>Venlafaxine Augmentation Treatment Resistant Depression</brief_title>
	<detailed_description>We examine efficacy Venlafaxine-HCL augmentation neuroleptic Quetiapine treatment resistant depression double-blind randomize clinical trial . Secondary objective evaluation pharmacogenetic factor contribute drug efficacy treatment resistant depression .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Female male inpatient major depressive disorder without psychotic feature depressive episode within bipolar I II disorder without psychotic feature Ages 20 70 year Total score great 18 Hamilton Depression Rating Scale Documentation least one ineffective antidepressant drug trial adequate dosage least 6 week current episode Other psychiatric axis I disorder mention Inclusion criterion Acute suicidality ( Item 3 Hamilton Depression Rating Scale great 2 ) Drug alcohol addiction Patients severe hepatic , cardiovascular , neurologic , metabolic malignant disorder Documentation report previous ineffective treatment trial venlafaxine , lamotrigine quetiapine Functional kidney disorder Untreated hypertension Acute treatment thyroid hormone ( le 3 month ) Pregnant nurse patient Women childbearing age without effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Treatment resistant depression</keyword>
	<keyword>Augmentation</keyword>
	<keyword>Pharmacogenetics</keyword>
</DOC>